GSK establishes $50m bioelectronic fund

GlaxoSmithKline (GSK), a UK-based pharmaceutical company, has launched Action Potential Venture Capital, a $50m strategic fund that will invest in companies that are pioneering bioelectronic medicines and technologies.

The fund’s name derives from electrical signals called “action potentials” that pass along nerves. Irregular or altered patterns may occur in association with diseases, and GSK believes that miniaturised devices, or bioelectronic medicines, can be designed to read these patterns and to treat disorders, acting as an interface between the peripheral nervous…